APA (7th ed.) Citation

Fasching, P. A., Decker, T., Hartkopf, A., Nusch, A., Heinrich, B. J., Kurbacher, C., . . . Reinisch, M. (2024). Efficacy, safety, and prognosis prediction in patients treated with ribociclib in combination with letrozole: Final results of phase 3b RIBECCA study in hormone receptor positive, human epidermal growth factor receptor-2 negative, locally advanced or metastatic breast cancer. European journal of cancer, 198, . https://doi.org/10.1016/j.ejca.2023.113480

Chicago Style (17th ed.) Citation

Fasching, Peter Andreas, et al. "Efficacy, Safety, and Prognosis Prediction in Patients Treated with Ribociclib in Combination with Letrozole: Final Results of Phase 3b RIBECCA Study in Hormone Receptor Positive, Human Epidermal Growth Factor Receptor-2 Negative, Locally Advanced or Metastatic Breast Cancer." European Journal of Cancer 198 (2024). https://doi.org/10.1016/j.ejca.2023.113480.

MLA (9th ed.) Citation

Fasching, Peter Andreas, et al. "Efficacy, Safety, and Prognosis Prediction in Patients Treated with Ribociclib in Combination with Letrozole: Final Results of Phase 3b RIBECCA Study in Hormone Receptor Positive, Human Epidermal Growth Factor Receptor-2 Negative, Locally Advanced or Metastatic Breast Cancer." European Journal of Cancer, vol. 198, 2024, https://doi.org/10.1016/j.ejca.2023.113480.